What you should know:
1. AGA developed an approach providers should take when treating patients with suspected OIC. They issued guidance for four major treatments.
2. AGA recommends traditional laxatives as a first-line treatment citing a moderate quality of evidence.
3. AGA issued several recommendations concerning Peripherally Acting μ-Opioid Receptor Antagonists use, over no treatment:
For patients with laxative refractory OIC, AGA recommends naldemedine with a high quality of evidence and naloxegol with a moderate quality of evidence
The AGA also issued a conditional recommendation for using methylnaltrexone, citing low quality of evidence.
4. The AGA did not recommend the use of internal secretagogues, lubiprostone, or selective 5-HT agonist, prucalopride, citing evidence gaps for both treatments.
Read the full recommendation here.
More articles on gastroenterology:
How ASC price transparency relates to value-based care, M&A activity & more: 4 insights
ACS grants Children’s Minnesota surgery center certification — 3 insights
HCA announces $1B public offering that could be used for acquisitions — 4 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
